A published protocol for the D-REM pragmatic randomized trial testing community paramedic home visits versus usual care in adults with diabetes and level 3 hypoglycemia. No outcomes are reported yet. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
An exploratory secondary analysis of two Phase 2 trials reports that oral orforglipron lowered blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP versus placebo, though no cardiovascular events were measured. PICO summary and expert commentary.
A nested qualitative process evaluation of the SuMMiT-D SMS intervention found patients described holistic, context-dependent benefits rather than measured adherence gains. PICO summary and expert commentary.
A secondary analysis of the FINGER lifestyle trial found that baseline dysglycaemia, especially OGTT-derived measures, was associated with less favourable cognitive and brain changes, while HbA1c showed mixed results. PICO summary and expert commentary.
A retrospective secondary analysis clustered app-usage data from 328 pregnant women in a gestational diabetes mHealth trial into three engagement types, with most classified as moderate users. PICO summary and expert commentary.
A secondary analysis of a Swedish RCT links higher engagement with a smartphone dietary-education app to modest dietary improvements, with no significant cardiometabolic marker changes, in adults with type 2 diabetes. PICO summary and expert commentary.
A multicentre open-label RCT testing whether 12-month mHealth home telemonitoring improves blood pressure and HbA1c versus standard care in older adults with hypertension and type 2 diabetes. PICO summary and expert commentary.
A 58-patient single-site implementation RCT of the community-health-worker-led TIME programme for uninsured Hispanic adults with type 2 diabetes, with PICO summary and expert commentary.
An open-label randomized trial in newly diagnosed type 2 diabetes found acarbose and vildagliptin both lowered plasma TMAO, with a greater fall on acarbose. PICO summary and expert commentary.
An MRI sub-study of the MemAID trial found that 24 weeks of intranasal insulin increased several hippocampal and medio-prefrontal resting-state connectivity measures versus placebo in 11 adults with type 2 diabetes. PICO summary and expert commentary.